Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Elisa Kieback"'
Autor:
Josefine Krüger, Matthias Obenaus, Igor Wolfgang Blau, Dana Hoser, Martin Vaegler, Hana Rauschenbach, Ioannis Anagnostopoulos, Korinna Jöhrens, Vivian Scheuplein, Elisa Kieback, Judith Böhme, Ann-Christin von Brünneck, Jan Krönke, Antonia Busse, Gerald Willimsky, Thomas Blankenstein, Antonio Pezzutto, Ulrich Keller, Axel Nogai
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/c30a3e990da440aeb648d5ee283c6126
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/5b055797f7f14ca79dd2c85ac3b4ab7b
Autor:
Elisa Kieback, Mikhail Steklov, Lucia Poncette, Lia Walcher, Lorenz Knackstedt, Friederike Knipping, Paul Najm, Paul Zschimmer, Panagiota A Sotiropoulou, Marleen van Loenen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ea92aa3a67334504abf4152d1fbfd389
Autor:
Ronald Simon, Thomas Blankenstein, Jennifer Oduro, Natalia Gorbokon, Christoph Fraune, Julia Bluhm, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Eugen Leo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ba13c44bf5c24d86a2ab8e2c4ce320de
Autor:
Matthias Leisegang, Thomas Blankenstein, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Ioannis Gavvovidis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5764ca011aa54c308996bdffb02e1ba6
Autor:
Fiona Thistlethwaite, Sylvie Rottey, Emiliano Calvo, Antonia Busse, Martin Wermke, Ralf Wolter, Thomas Blankenstein, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Eugen Leo, Ioannis Gavvovidis, Marie-Luise Goebeler, Nuria Kotecki, Carolina Perdomo-Ortiz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/795cb33ed4024620a0e2bdd6fb8742d4
Autor:
Karin Wisskirchen, Kai Metzger, Sophia Schreiber, Theresa Asen, Luise Weigand, Christina Dargel, Klaus Witter, Elisa Kieback, Martin F Sprinzl, Wolfgang Uckert, Matthias Schiemann, Dirk H Busch, Angela M Krackhardt, Ulrike Protzer
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182936 (2017)
T-cell therapy of chronic hepatitis B is a novel approach to restore antiviral T-cell immunity and cure the infection. We aimed at identifying T-cell receptors (TCR) with high functional avidity that have the potential to be used for adoptive T-cell
Externí odkaz:
https://doaj.org/article/36657d80dd584b9cbf50469f96db5884
Autor:
Felix K M Lorenz, Susanne Wilde, Katrin Voigt, Elisa Kieback, Barbara Mosetter, Dolores J Schendel, Wolfgang Uckert
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0121633 (2015)
Codon optimization of nucleotide sequences is a widely used method to achieve high levels of transgene expression for basic and clinical research. Until now, immunological side effects have not been described. To trigger T cell responses against huma
Externí odkaz:
https://doaj.org/article/1dc7330131824a3e95242ca3e8507f4b
Autor:
Emiliano Calvo, Antonia Busse, Martin Wermke, Fiona C Thistlethwaite, Ralf Wolter, Sylvie Rottey, Matthias Obenaus, Ioannis Gavvovidis, Marie-Luise Goebeler, Vivian Scheuplein, Elisa Kieback, Eugen Leo, Nuria Kotecki, Carolina Perdomo-Ortiz, Thomas Blankenstein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundMelanoma-associated antigen 1 (MAGE-A1) is a cancer-testis antigen with highly selective expression in testis (which is an immune privileged site) and in multiple high unmet medical need cancers. Therefore, it represents an attractive targe
Autor:
Alexei Leliavski, Lorenz Knackstedt, Jennifer Oduro, Claudia Selck, Arunraj Dhamodaran, Thomas Blankenstein, Elisa Kieback, Lucia Poncette
Publikováno v:
Cancer Research. 82:5507-5507
Background T cell receptor (TCR)-engineered T cell therapy (TCR-T) is a promising therapeutic modality to address key limitations of targeting solid tumors. Neoantigens are excellent therapeutic targets for TCR-T cell therapy, because they are highly